Literature DB >> 12359732

Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity.

Sharron H Francis1, Emmanuel P Bessay, Jun Kotera, Kennard A Grimes, Li Liu, W Joseph Thompson, Jackie D Corbin.   

Abstract

Substrate binding to the phosphodiesterase-5 (PDE5) catalytic site increases cGMP binding to the regulatory domain (R domain). The latter promotes PDE5 phosphorylation by cyclic nucleotide-dependent protein kinases, which activates catalysis, enhances allosteric cGMP binding, and causes PDE5A1 to apparently elongate. A human PDE5A1 R domain fragment (Val(46)-Glu(539)) containing the phosphorylation site (Ser(102)) and allosteric cGMP-binding sites was studied. The rate, cGMP dependence, and stoichiometry of phosphorylation of the PDE5 R domain by the catalytic subunit of cAMP-dependent protein kinase are comparable with that of the holoenzyme. Migration in native polyacrylamide gels suggests that either cGMP binding or phosphorylation produces distinct conformers of the R domain. Phosphorylation of the R domain increases affinity for cGMP approximately 10-fold (K(D) values 97.8 +/- 17 and 10.0 +/- 0.5 nm for unphospho- and phospho-R domains, respectively). [(3)H]cGMP dissociates from the phospho-R domain with a single rate (t(12) = 339 +/- 30 min) compared with the biphasic pattern of the unphospho-R domain (t(12) = 39.0 +/- 4.8 and 265 +/- 28 min, for the fast and slow components, respectively). Thus, cGMP-directed regulation of PDE5 phosphorylation and the resulting increase in cGMP binding affinity occur largely within the R domain. Conformational change(s) elicited by phosphorylation of the R domain within the PDE5 holoenzyme may also cause or participate in stimulating catalysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359732     DOI: 10.1074/jbc.M206088200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.

Authors:  Florian Mullershausen; Michael Russwurm; Doris Koesling; Andreas Friebe
Journal:  Mol Biol Cell       Date:  2004-07-07       Impact factor: 4.138

2.  Characterization of conformational changes and protein-protein interactions of rod photoreceptor phosphodiesterase (PDE6).

Authors:  Suzanne L Matte; Thomas M Laue; Rick H Cote
Journal:  J Biol Chem       Date:  2012-04-18       Impact factor: 5.157

3.  Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6.

Authors:  Xiu-Jun Zhang; Karyn B Cahill; Arye Elfenbein; Vadim Y Arshavsky; Rick H Cote
Journal:  J Biol Chem       Date:  2008-09-08       Impact factor: 5.157

4.  Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.

Authors:  Jackie D Corbin; Roya Zoraghi; Sharron H Francis
Journal:  Cell Signal       Date:  2009-08-06       Impact factor: 4.315

5.  The unexpected evolution of basic science studies about cyclic nucleotide action into a treatment for erectile dysfunction.

Authors:  Jackie Corbin
Journal:  J Biol Chem       Date:  2014-12-11       Impact factor: 5.157

6.  Structures of the PelD cyclic diguanylate effector involved in pellicle formation in Pseudomonas aeruginosa PAO1.

Authors:  Zhi Li; Jui-Hui Chen; Yue Hao; Satish K Nair
Journal:  J Biol Chem       Date:  2012-07-17       Impact factor: 5.157

7.  Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

Authors:  B Musicki; S Karakus; W Akakpo; F H Silva; J Liu; H Chen; B R Zirkin; A L Burnett
Journal:  Andrology       Date:  2017-11-16       Impact factor: 3.842

Review 8.  Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights.

Authors:  Clemens C Heikaus; Jayvardhan Pandit; Rachel E Klevit
Journal:  Structure       Date:  2009-12-09       Impact factor: 5.006

Review 9.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012

10.  Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity.

Authors:  Gentzon Hall; Janelle Rowell; Federica Farinelli; Rasheed A Gbadegesin; Peter Lavin; Guanghong Wu; Alison Homstad; Andrew Malone; Thomas Lindsey; Ruiji Jiang; Robert Spurney; Gordon F Tomaselli; David A Kass; Michelle P Winn
Journal:  Am J Physiol Renal Physiol       Date:  2014-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.